CytomX Therapeutics (CTMX) Current Assets (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Current Assets came in at $353.1 million in Q1 2026, up 307.6% YoY from $86.6 million in Q1 2025, and up 145.34% on a QoQ basis from $143.9 million in Q4 2025.
CytomX Therapeutics (CTMX) Current Assets (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Current Assets data on file, last reported at $353.1 million in Q1 2026.
- Quarterly Current Assets rose 307.6% year-over-year to $353.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $353.1 million (up 307.6% YoY) and the FY2025 annual result came in at $143.9 million, up 34.12% from the prior year.
- Current Assets rose to $353.1 million in Q1 2026, from $143.9 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $353.1 million in Q1 2026 to a low of $86.6 million in Q1 2025.
- A 5-year average of $186.0 million and a median of $182.9 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2025 — Current Assets slumped 48.2% — and 2026, when it surged 307.6%.
- Tracing CTMX's Current Assets over 5 years: stood at $237.1 million in 2022, then slipped by 22.85% to $182.9 million in 2023, then sank by 41.34% to $107.3 million in 2024, then jumped by 34.12% to $143.9 million in 2025, then surged by 145.34% to $353.1 million in 2026.
- The last three Current Assets figures came in at $353.1 million (Q1 2026), $143.9 million (Q4 2025), and $149.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 373.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 373.16 Mn |
| Mar 31, 2026 | 353.10 Mn |
| Dec 31, 2025 | 143.92 Mn |
| Sep 30, 2025 | 149.22 Mn |
| Jun 30, 2025 | 164.62 Mn |
| Mar 31, 2025 | 86.63 Mn |
| Dec 31, 2024 | 107.31 Mn |
| Sep 30, 2024 | 124.18 Mn |
| Jun 30, 2024 | 143.08 Mn |
| Mar 31, 2024 | 167.25 Mn |
| Dec 31, 2023 | 182.94 Mn |
| Sep 30, 2023 | 201.20 Mn |
| Jun 30, 2023 | 187.80 Mn |
| Mar 31, 2023 | 212.28 Mn |
| Dec 31, 2022 | 237.10 Mn |
| Sep 30, 2022 | 200.28 Mn |
| Jun 30, 2022 | 232.77 Mn |
| Mar 31, 2022 | 268.44 Mn |
| Dec 31, 2021 | 310.30 Mn |
| Sep 30, 2021 | 241.00 Mn |